Legend's new cell therapy shows promise for blood cancer patients

• All six patients in the higher-dose cohort responded to treatment, with five showing complete response; CAR-T cells were detected in blood for up to 116 days
• The therapy eliminates the need for extracting, re-engineering, and reinfusing cells externally, potentially making treatment more accessible as an 'off-the-shelf' option
• No dose-limiting toxicities, serious adverse events, or deaths were reported; infusion-related reactions in nine patients resolved within a median of two days

Legend Biotech's In Vivo CAR-T Therapy Shows Promise in Early Trial

Key Development:

Legend Biotech announced positive early-stage results for LB2501, an experimental in vivo CAR-T therapy for B-cell non-Hodgkin lymphoma. Unlike traditional CAR-T treatments requiring ex vivo cell modification, this therapy generates disease-fighting cells directly within patients through a single infusion.

Trial Results:

As of April 1, 12 patients with relapsed/refractory B-cell non-Hodgkin lymphoma were treated across two dose levels. In the higher-dose cohort, all six patients responded to treatment, with five achieving complete response. CAR-T cells were detected in peripheral blood for up to 116 days.

Safety Profile:

The therapy demonstrated a favorable safety profile with no dose-limiting toxicities, serious adverse events, or fatalities reported. Nine patients experienced infusion-related reactions, which resolved within a median of two days.

Market Significance:

This "off-the-shelf" approach could simplify treatment delivery and expand access for patients unable to receive traditional CAR-T therapies, which require time-consuming cell extraction, re-engineering, and reinfusion. The technology positions Legend competitively in an increasingly attractive space, with major pharmaceutical companies like AstraZeneca and Eli Lilly recently striking deals in the in vivo CAR-T field.

Company Statement:

CEO Ying Huang emphasized the therapy's potential to streamline treatment and improve patient access. Legend noted that while longer follow-up is needed, the data highlights LB2501's potential as a scalable, readily accessible immunotherapy for B-cell malignancies.

Implications:

The positive early data could accelerate development of next-generation CAR-T therapies and strengthen Legend's position in the competitive cell therapy market.